
DBVT Stock Forecast & Price Target
DBVT Analyst Ratings
Bulls say
DBV Technologies SA is positioned favorably due to the successful Phase 3 VITESSE trial, which met its primary endpoint, significantly enhancing confidence in the Viaskin Peanut program for peanut-allergic children aged 4-7. Continued treatment has shown efficacy improvements and reduced reaction severity over time, which suggests a compelling long-term benefit profile beyond initial treatment phases. With expectations for a Biologics License Application (BLA) submission in the first half of 2026 and an increased probability of success for the Viaskin platform, the outlook for DBV Technologies remains positive.
Bears say
DBV Technologies SA experienced a significant financial setback in FY25, reporting a net loss of approximately $147 million, equating to a loss of $1.05 per share. Key risks impacting the company's outlook include potential failures in clinical studies, challenges in securing regulatory approval, and a smaller-than-expected commercial opportunity due to market size, competition, and pricing dynamics. Furthermore, without evidence of clinical significance and safety, as well as potential reimbursement issues, DBV Technologies may struggle to generate revenue and see limited product adoption, thereby dampening its overall market potential.
This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
DBVT Analyst Forecast & Price Prediction
Start investing in DBVT
Order type
Buy in
Order amount
Est. shares
0 shares